Form 4: Kiora Pharmaceuticals Director Acquires Stock Options

Lisa Walters-Hoffert, a director of Kiora Pharmaceuticals, acquired stock options to purchase 1,778 shares of common stock on July 1, 2024.

Summary

• On July 1, 2024, Lisa Walters-Hoffert, a director at Kiora Pharmaceuticals, acquired stock options.
• These options grant her the right to purchase 1,778 shares of Kiora Pharmaceuticals' common stock at an exercise price of $4.35 per share.
• The options were granted under the company's 2024 Equity Incentive Plan.
• The options will become fully exercisable on July 1, 2025, and expire on July 1, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. It doesn't inherently indicate positive or negative performance.

Positives

• The grant of stock options to a director aligns her interests with those of the shareholders.
• The vesting period of one year suggests a commitment to the company's long-term success.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of one year is fairly standard, as it encourages continued service and commitment to the company's goals.
• The exercise price is set at \$4.35, which may be at or above the current market price, depending on the stock's valuation on the grant date.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, director, Kiora Pharmaceuticals, equity incentive plan, beneficial ownership, Form 4